Insider Selling: Aduro Biotech, Inc. (ADRO) COO Sells $159,400.00 in Stock
Aduro Biotech, Inc. (NASDAQ:ADRO) COO Gregory W. Schafer sold 20,000 shares of the business’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $7.97, for a total transaction of $159,400.00. Following the sale, the chief operating officer now directly owns 155,677 shares of the company’s stock, valued at $1,240,745.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Aduro Biotech, Inc. (NASDAQ ADRO) opened at $7.95 on Friday. Aduro Biotech, Inc. has a 1 year low of $6.01 and a 1 year high of $15.52.
Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). The firm had revenue of $3.79 million for the quarter, compared to analysts’ expectations of $4.04 million. Aduro Biotech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The business’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.54) earnings per share. equities research analysts forecast that Aduro Biotech, Inc. will post -1.28 earnings per share for the current year.
WARNING: “Insider Selling: Aduro Biotech, Inc. (ADRO) COO Sells $159,400.00 in Stock” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/insider-selling-aduro-biotech-inc-adro-coo-sells-159400-00-in-stock/1695869.html.
Institutional investors and hedge funds have recently bought and sold shares of the company. Legal & General Group Plc increased its holdings in shares of Aduro Biotech by 11.2% during the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 1,043 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in Aduro Biotech in the 3rd quarter worth approximately $127,000. Tudor Investment Corp ET AL increased its holdings in Aduro Biotech by 34.8% in the 1st quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock worth $166,000 after buying an additional 3,984 shares during the period. Parametric Portfolio Associates LLC increased its holdings in Aduro Biotech by 15.9% in the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after buying an additional 2,119 shares during the period. Finally, SG Americas Securities LLC acquired a new position in Aduro Biotech in the 3rd quarter worth approximately $167,000. Hedge funds and other institutional investors own 34.01% of the company’s stock.
A number of brokerages have recently issued reports on ADRO. HC Wainwright set a $18.00 target price on shares of Aduro Biotech and gave the company a “buy” rating in a research note on Wednesday, November 1st. Oppenheimer Holdings, Inc. began coverage on shares of Aduro Biotech in a research note on Monday, October 30th. They set a “buy” rating and a $15.00 target price for the company. William Blair reissued an “outperform” rating on shares of Aduro Biotech in a research note on Monday, October 2nd. BidaskClub lowered shares of Aduro Biotech from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th. Finally, Canaccord Genuity set a $30.00 target price on shares of Aduro Biotech and gave the company a “buy” rating in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $19.14.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.